



COMITE DE DERECHOS HUMANOS (IRB)  
INSTITUTIONAL REVIEW BOARD

**Date:** December 21, 2017

**Protocol Number:** A7080316

**Principal Investigator:** Edna Acosta Pérez

**Department / Division:** School of Public Health

**Sponsor:**

**Title:** Monitoring and Evaluation for the Zika Contraception Access Network (Z-CAN): Phase I Evaluación y monitor de la Red de Acceso a Anticonceptivos y el Zika (Z-CAN): Fase II

This is to certify that this continuing review #1 was evaluated on **December 21, 2017** and meets **expedite** IRB review category #7. The research proposal was **approved**. The approval period for this study is **December 21, 2017** to **December 21, 2018**.

This action involves:

Data Analysis and FU

The following documents were reviewed under this submission:

Informed Consent Document in Spanish

For additional information please contact Human Research Subjects Protection Office at 787-758-2525 exts. 2510 to 2515; e-mail [opphi.rcm@upr.edu](mailto:opphi.rcm@upr.edu).

Cordially,

Adelma Rivera Cruz, RN, BSN, CCRC  
Vice Chairperson IRB 1

bcg

1. Research must be conducted according to the proposal that was approved by the IRB.
2. Changes to the protocol or its related consent document must be approved by the IRB prior to implementation.
3. All serious or unexpected adverse events/drug reactions should be reported.
4. Each subject should receive a copy of the consent document, if appropriate.
5. Records must be retained for at least three years.
6. Any future correspondence should include the IRB identification number provided and the study title.